BAYN Intrinsic Valuation and Fundamental Analysis - Bayer AG - Alpha Spread

Bayer AG
XETRA:BAYN

Watchlist Manager
Bayer AG Logo
Bayer AG
XETRA:BAYN
Watchlist
Price: 26.265 EUR -1.89% Market Closed
Market Cap: 25.8B EUR
Have any thoughts about
Bayer AG?
Write Note

Intrinsic Value

The intrinsic value of one BAYN stock under the Base Case scenario is 117.217 EUR. Compared to the current market price of 26.265 EUR, Bayer AG is Undervalued by 78%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BAYN Intrinsic Value
117.217 EUR
Undervaluation 78%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Bayer AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BAYN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BAYN?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Bayer AG

Provide an overview of the primary business activities
of Bayer AG.

What unique competitive advantages
does Bayer AG hold over its rivals?

What risks and challenges
does Bayer AG face in the near future?

Summarize the latest earnings call
of Bayer AG.

What significant events have occurred
in Bayer AG over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bayer AG.

Provide P/S
for Bayer AG.

Provide P/E
for Bayer AG.

Provide P/OCF
for Bayer AG.

Provide P/FCFE
for Bayer AG.

Provide P/B
for Bayer AG.

Provide EV/S
for Bayer AG.

Provide EV/GP
for Bayer AG.

Provide EV/EBITDA
for Bayer AG.

Provide EV/EBIT
for Bayer AG.

Provide EV/OCF
for Bayer AG.

Provide EV/FCFF
for Bayer AG.

Provide EV/IC
for Bayer AG.

Show me price targets
for Bayer AG made by professional analysts.

What are the Revenue projections
for Bayer AG?

How accurate were the past Revenue estimates
for Bayer AG?

What are the Net Income projections
for Bayer AG?

How accurate were the past Net Income estimates
for Bayer AG?

What are the EPS projections
for Bayer AG?

How accurate were the past EPS estimates
for Bayer AG?

What are the EBIT projections
for Bayer AG?

How accurate were the past EBIT estimates
for Bayer AG?

Compare the revenue forecasts
for Bayer AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bayer AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bayer AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bayer AG compared to its peers.

Compare the P/E ratios
of Bayer AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Bayer AG with its peers.

Analyze the financial leverage
of Bayer AG compared to its main competitors.

Show all profitability ratios
for Bayer AG.

Provide ROE
for Bayer AG.

Provide ROA
for Bayer AG.

Provide ROIC
for Bayer AG.

Provide ROCE
for Bayer AG.

Provide Gross Margin
for Bayer AG.

Provide Operating Margin
for Bayer AG.

Provide Net Margin
for Bayer AG.

Provide FCF Margin
for Bayer AG.

Show all solvency ratios
for Bayer AG.

Provide D/E Ratio
for Bayer AG.

Provide D/A Ratio
for Bayer AG.

Provide Interest Coverage Ratio
for Bayer AG.

Provide Altman Z-Score Ratio
for Bayer AG.

Provide Quick Ratio
for Bayer AG.

Provide Current Ratio
for Bayer AG.

Provide Cash Ratio
for Bayer AG.

What is the historical Revenue growth
over the last 5 years for Bayer AG?

What is the historical Net Income growth
over the last 5 years for Bayer AG?

What is the current Free Cash Flow
of Bayer AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bayer AG.

Business Breakdown

Bayer AG, a German multinational corporation, stands as a pivotal player in the fields of pharmaceuticals, consumer health, agricultural products, and biotechnology. Founded in 1863, Bayer has transformed over the decades into a global powerhouse, renowned for its commitment to innovation and sustainability. The company is best known for its development of influential medications while also offering a broad portfolio of consumer health products, including over-the-counter medications and nutritional supplements. Bayer’s robust research and development arm fuels its growth, focusing on areas such as oncology, cardiology, and women's health, which showcases its dedication to addressing signifi...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bayer AG

Current Assets 40.1B
Cash & Short-Term Investments 10B
Receivables 17B
Other Current Assets 13.1B
Non-Current Assets 79.7B
Long-Term Investments 3.2B
PP&E 13.5B
Intangibles 55.9B
Other Non-Current Assets 7.2B
Current Liabilities 31.6B
Accounts Payable 6.1B
Other Current Liabilities 25.4B
Non-Current Liabilities 52.6B
Long-Term Debt 37.4B
Other Non-Current Liabilities 15.2B
Efficiency

Earnings Waterfall
Bayer AG

Revenue
47.1B EUR
Cost of Revenue
-19.8B EUR
Gross Profit
27.4B EUR
Operating Expenses
-25.1B EUR
Operating Income
2.2B EUR
Other Expenses
-3.5B EUR
Net Income
-1.3B EUR

Free Cash Flow Analysis
Bayer AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q2, revenue rose by 3% to €11.1 billion, despite a 16% drop in EBITDA to €2.1 billion, driven by unfavorable product mix and higher incentive provisions. Free cash flow improved significantly to €1.3 billion. Crop Science saw a 1% sales increase, with strong soybean growth mitigating corn declines. Pharma grew by 4%, led by new products like Nubeqa and Kerendia. Consumer Health returned to growth, driven by innovations in Dermatology and Digestive Health. Full-year guidance was confirmed with an expected sales increase of 0% to 3% in Pharma and pressure from generics on Xarelto.

What is Earnings Call?
Fundamental Scores

BAYN Profitability Score
Profitability Due Diligence

Bayer AG's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

50/100
Profitability
Score

Bayer AG's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

BAYN Solvency Score
Solvency Due Diligence

Bayer AG's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Short-Term Solvency
Average D/E
Positive Net Debt
30/100
Solvency
Score

Bayer AG's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BAYN Price Targets Summary
Bayer AG

Wall Street analysts forecast BAYN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BAYN is 33.428 EUR with a low forecast of 25.25 EUR and a high forecast of 64.05 EUR.

Lowest
Price Target
25.25 EUR
4% Downside
Average
Price Target
33.428 EUR
27% Upside
Highest
Price Target
64.05 EUR
144% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BAYN?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Previous Payment
-
Today
Next Payment
-
Today
Oct 12, 2024
Previous Payment
-
Next Payment
-
Ex-Dividend Date
-
Want to learn more about BAYN dividends?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for BAYN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

BAYN News

Other Videos

Profile

Bayer AG Logo
Bayer AG

Country

Germany

Industry

Pharmaceuticals

Market Cap

25.8B EUR

Dividend Yield

0.42%

Description

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 99,637 full-time employees. The firm's segments are Pharmaceuticals, Consumer Health, Crop Science. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The firm is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds.

Contact

NORDRHEIN-WESTFALEN
Leverkusen
Kaiser-Wilhelm-Allee 1
+49214301.0
www.bayer.de

IPO

1997-11-28

Employees

99 637

Officers

See Also

Discover More
What is the Intrinsic Value of one BAYN stock?

The intrinsic value of one BAYN stock under the Base Case scenario is 117.217 EUR.

Is BAYN stock undervalued or overvalued?

Compared to the current market price of 26.265 EUR, Bayer AG is Undervalued by 78%.

Back to Top